Abstract
Integrins are important adhesion receptors in all Metazoa that transmit conformational change bidirectionally across the membrane. Integrin α and β subunits form a head and two long legs in the ectodomain and span the membrane. Here, we define with crystal structures the atomic basis for allosteric regulation of the conformation and affinity for ligand of the integrin ectodomain, and how fibrinogen-mimetic therapeutics bind to platelet integrin αIIbbβ3. Allostery in the β3 I domain alters three metal binding sites, associated loops and a α1- and α7-helices. Piston-like displacement of the a 7-helix causes a 62° reorientation between the β3 I and hybrid domains. Transmission through the rigidly connected plexin/semaphorin/integrin (PSI) domain in the upper β3 leg causes a 70Å separation between the knees of the α and β legs. Allostery in the head thus disrupts interaction between the legs in a previously described low-affinity bent integrin conformation, and leg extension positions the high-affinity head far above the cell surface.
Integrins are adhesion receptors that transmit signals bidirectionally across the plasma membrane1–4. Rearrangements in integrin extracellular, transmembrane and cytoplasmic domains underlie diverse biological processes, including cell migration, morpho-genesis, immune responses and vascular haemostasis. The platelet-specific integrin αIIbβ3 is important in both the arrest of bleeding at sites of vascular injury and pathological thrombosis leading to heart attacks and stroke. Loss of the vascular endothelium results in platelet deposition, and receptors for collagen, thrombin and other agonists then initiate platelet signalling, resulting in changes in the cytoplasmic domains of αIIbβ3 that are transmitted into conformational changes in the extracellular domains. This leads to high-affinity binding of fibrinogen and von Willebrand factor, resulting in crosslinking of platelets into aggregates by these multivalent ligands, and activation by αIIbβ3 of further intracellular signals. Mutations of either αiib or β3 result in the bleeding disorder Glanzmann thrombasthenia and drugs that inhibit ligand binding to αIIbβ3 are effective in preventing and treating coronary artery thrombosis5.
Global structural rearrangements in integrin extracellular domains are demonstrated by electron microscopy and exposure of activation epitopes known as ligand-induced binding sites (LIBS)2,4. Negative stain electron microscopy with image averaging of integrins has demonstrated three overall conformations of the extracellular domain3,6 (Fig. 1a–c). A low-affinity, bent conformation (Fig. 1a) matches αVβ3 crystal structure7,8. An extended form with a ‘closed’ headpiece conformation matching that in the crystal structure represents an intermediate affinity state (Fig. 1b). Ligand-binding induces a high-affinity, extended form with an ‘open’ headpiece, in which the angle between the β I and hybrid domains changes from acute to obtuse3,6 (Fig. 1c). This marked change in tertiary structure is supported by mutational studies3,6,9–11 and solution X-ray scattering12. Ligand-mimetic compounds induce the extended, open headpiece conformation of integrins in solution and on the cell surface3,6,10–13, and LIBS epitope exposure14. In contrast, when a ligand-mimetic is soaked into preformed crystals containing the bent integrin conformation with the closed headpiece, binding induces only localized structural changes near the ligand binding site8.
In the low-affinity bent structure, the α and β subunit ecto-domain carboxy termini7 and transmembrane domains are closely associated15,16, and transmission of activation signals across the membrane involves separation between the α and β transmembrane and cytoplasmic domains16–18. How allostery could be relayed between the integrin transmembrane domains, legs and ligand-binding head has been unclear. We have proposed that the conformation of the ligand-binding site atop the integrin β I domain could be transmitted to the outward swing of the β hybrid domain between the closed and open headpiece conformations (Fig. 1b, c) by a piston-like β I domain α7-helix motion similar to that seen in integrina βI domains3,6. However, in the absence of atomic views of the high-affinity integrin state, different opinions about its conformation have been put forward.
Here, atomic structures of αIIbβ3 fragments demonstrate the high-affinity, open conformation of the integrin headpiece, its binding to therapeutic antagonists, and the allosteric movements that link the ligand binding site of βI domains to α7-helix displacement and outward swing of the hybrid domain. The β3 hybrid and PSI domains act as a rigid lever that transmits and amplifies this motion, resulting in a 70Å separation between the α and β legs at their knees that favours leg extension.
Overall structure of an open integrin headpiece
Two crystal forms each contain αiib residues 1–452 comprising the yyβ-propeller domain and β3 residues 1–440 including the β I, hybrid and PSI domains (Fig. 2a, b and Supplementary Table 1). Crystal form A contains one copy per asymmetric unit of the αIIbβ3 headpiece bound to 10E5 Fab19 (Fig. 2a), and ligand-mimetic antagonist or cacodylate ion bound to the β3 I domain metal-ion-dependent adhesion site (MIDAS) (2.7–3.1Å resolution). Crystal form B contains no Fab and three independent, cacodylate-bound αIIbβ3 molecules per asymmetric unit (2.9Å resolution). The four independent αIIbβ3 headpiece fragments from the two crystal forms adopt similar conformations, with only minor differences in the angle between the β I and hybrid domains (Fig. 2b). Five N-linked glycans are resolved, including one in a form A crystal lattice contact with seven carbohydrate residues (Fig. 2a). Residues 55–77 in our β3 hybrid domain structures have a different sequence-structure register than previousβ3 structures (Supplementary Material).
Our crystal structures reveal an open, high-affinity conformation of the αIIbβ3 headpiece similar to that in electron microscopy averages of the αVβ3 ectodomain in which ligand binding induced the extended conformation with the open headpiece3 (Fig. 1c). Relative to the bent aVβ3 crystal structure with the closed, lowaffinity conformation of the headpiece3,7, the α7-helix of the β3 I domain moves downward, causing the hybrid and PSI domains to swing away from the α subunit by 62° (Fig. 2d). The angle between the β I and hybrid domains visualized here is in excellent agreement with that found by electron microscopy for ligandedaVβ3 (ref. 3) and the α5b1 headpiece bound to FN3 module 10 of fibronectin6 (Fig. 2e). Ligand-mimetic antagonists are known to induce the conformation of αIIbβ3 with high affinity for fibrinogen14. Crystallization in the open conformation may also have been facilitated by truncation of the integrin tailpiece, which participates in extensive interfaces that stabilize the bent αVβ3 conformation3. The conformation characterized here termed ‘liganded-open’ was obtained by co-crystallization with ligand, enabling equilibration to the most favoured ligand-bound conformation before crystallization. By contrast, crystals of αVβ3 were previously formed in the bent, low-affinity conformation which we term ‘unliganded-closed’, and a ligand-mimetic antagonist was then soaked-in to obtain what we term the ‘liganded-closed’ conformation8. Crystal packing contacts are required for maintenance of the bent, liganded-closed conformation, because in solution addition of the same ligand to bent αVβ3 induces leg extension and conversion of the headpiece to the open conformation3.
Ligand binding to αIIbβ3
Small molecule antagonists bind to a small pocket atop the integrin head formed by loops from the αiib β-propeller and β3 I domain (Figs 2a and 3a–d). The binding site for the macromolecular ligand fibrinogen is more extensive, as revealed by the positions of residues shown by mutation to affect binding (Fig. 3a). In macromolecular recognition, the β3 specificity determining loop (SDL) and four αiib β-propeller loops that form a cap subdomain are particularly important, with 71% of fibrinogen-sensitive αiib mutations mapping to the latter20. The αiib-specific 10E5 Fab binds solely to the αiib cap subdomain (Fig. 2a, Supplementary Material and Supplementary Fig. 2) and has no effect on its conformation (Fig. 2b). Binding of small molecules is not blocked by 10E5, as shown by their co-crystallization (Figs 2a and 3a–d), and thus blocks binding of fibrinogen to αIIbβ3 (ref. 19) solely by occluding the macromolecular recognition site on the αiib cap subdomain. By contrast, the β3 specific-7E3 Fab, abciximab, blocks fibrinogen- binding by binding to residues in theβ3 SDL5,21.
The cap subdomain helps form the drug-binding pocket as well as the macromolecular recognition surface on αiib. It is comprised of four long insertions or loops in the β-propeller domain (Supplementary Fig. 1a). Insert 3 forms an a -helix in the αiib drug-binding pocket (Fig. 3a–d), and in integrina subunits that contain I domains forms the ligand-bindinga I domain4. Inserts 1 and 2 form a four-stranded anti-parallel β-sheet in the centre of the cap subdomain that is buttressed on one side by the α-helix and loop of insert 4, and on the other side by the β3 SDL (Fig. 2a). Alternative splicing of cap insert 4 can regulate ligand-binding specificity22,23.
The greatest structural differences between the αiib and αV β-propellers are in cap inserts 1, 2 and 3 (Fig. 2d). The β3 SDL closely associates with the cap subdomain, and structural variation between αiib and αV appears to be responsible for the different β3 SDL conformations inαIIbβ3 and αVβ3 (Figs 2d and 3d compared with 3f). By contrast, the remainder of theαiib and αVb-propellers are highly conserved structurally, with a root mean square deviation of 1.4Å for 391 residues. The hub of theβ-propeller that associates with the β I domain is especially conserved, enabling up to eleven diverse integrin α-subunits to bind to a singleb α-subunit24. At their current resolutions of 2.7Å and 3.1Å, respectively, there is no significant difference between liganded-open αIIbβ3 and unliganded-closed αVβ3 in orientation between the β-propeller and β I domains (Fig. 2d).
All crystals reported here were formed in the presence of the physiological cations Ca2+ and Mg2+. Three metal binding sites are present in the β3 I domain in the drug-binding pocket8 (Figs 2a and 3a–f). In the middle site, the MIDAS, a Mg2+ ion coordinates a carboxyl group present in each of the three co-crystallized ligandmimetic αIIbβ3 antagonists (Fig. 3a–d). The cacodylate ion that is bound to form A (Fig. 3e) and form B crystals binds in the same way as the carboxyl group of the ligand-mimetics, with one oxygen coordinating the MIDAS Mg2+ and the other hydrogen-bonding to two backbone amides. The cacodylate may thus act as a pseudo-ligand, and stabilize the open β subunit I domain conformation similarly to pseudoligand lattice contacts that stabilize the open α subunit I domain conformation25–27. Ca2+ was assigned at the two sites adjacent to the MIDAS on the basis of Yb3+ soaking data and coordination chemistry (see Methods). The site distal to the β-propeller is termed adjacent to MIDAS (ADMIDAS). The site near the β-propeller is termed ligand-induced metal binding site (LIMBS). The LIMBS is occupied in the open αIIbβ3 structure even when only a cacodylate pseudoligand is bound (Fig. 3e).
Two drugs used in prevention and treatment of coronary artery thrombosis, tirofiban and eptifibatide5, as well as Merck compound L-739758 (Fig. 3a–d), antagonize binding of fibrinogen to αIIbβ3. These compounds were developed as mimics of the Arg-Gly-Asp sequence that is found in a wide variety of integrin glycoprotein ligands, and the αIIbβ3-binding sequence in fibrinogen, Lys-Gln-Ala-Gly-Asp-Val28,29,30. In addition to αIIbβ3, the integrins αVb1, αVβ3, αVb5, αVb6, αVb8, α5b1 and α8b1 recognize the Arg-Gly-Asp motif. Therefore, a major focus of pharmaceutical development was selective inhibition of αIIbβ3, particularly in comparison to the closely related αVβ3 integrin. Our co-crystal structures (Fig. 3b–d), and comparison to an αVβ3-selective compound soaked into αVβ3 crystals (Fig. 3f)8, reveal the basis for drug binding and selectivity (see Supplementary Material for details). Each drug has a basic moiety that mimics the arginine in Arg-Gly-Asp or the lysine in the fibrinogen sequence, and a carboxyl group that mimics the aspartic acid. Selectivity for αIIbβ3 and αVβ3 is conferred by a longer and shorter distance, respectively, between the basic and acidic moieties of peptidomimetics (Fig. 3d, f), which can be adjusted by the constraints on the cyclic ring that bears the basic and aspartic acid residues, and the length of the basic residue side chain28,29. Our structures show that this is because the basic ligand-mimetic side chain must reach further into the deeper β-propeller pocket of αiib to hydrogen-bond to αiib-Asp 224 (Fig. 3b–d), whereas in the αVb-propeller the hydrogen-bonding residues Asp 150 and Asp 218 are nearer in its shallower pocket (Fig. 3f). Furthermore, Asp 218 in aV is replaced by Phe 231 in αiib, favouring contacts with longer aliphatic moieties (Fig. 3b–d, f).
A large number of snake venom disintegrins with Arg-Gly-Asp sequences have evolved to inhibit haemostasis but are not αiibb3-selective. An unusual, αIIbβ3-selective disintegrin with a Lys-Gly- Asp-Trp sequence led to the development of eptifibatide31. The lysine with its longer aliphatic side chain than arginine confers selectivity, whereas the tryptophan confers high affinity. In an independent drug development programme, exosite substituents such as pyridyl sulphonamide were found that substantially increase affinity30 (Fig. 3c) and that occupy the same position in the drug-binding pocket as the tryptophan residue (Fig. 3d).
Comparison to the cacodylate-bound structure (Fig. 3e) demonstrates that the drug-binding pocket in αIIbβ3 is rigid, with the contacting residues adopting the same conformation with or without the drugs. This helps account for high affinity, despite burial of a solvent-accessible surface area of only 300–390Å2 on the three drugs.
An open, high-affinity conformation for integrin β I domains
Comparisons among unliganded-closed αVβ3, liganded-closed αVβ3 and liganded-open αIIbβ3 reveal the atomic basis for communication of allostery between the ligand binding site in the β3 I domain and other integrin domains (Figs 2d and 4a, c, d, e; Supplementary Movie 1). In liganded-open αIIbβ3 compared with unliganded-closed αVβ3, concerted movements in the β3 I domain occur in the ligand-binding b 1–a 1 loop, the a 1-helix, the α 1–b 2 loop, the α2-helix, the β 6–a 7 loop and the α7-helix. Movements in the ligand- and metal-binding β 1–a 1 loop are similar in both liganded structures, but greater in magnitude for the liganded-open structure than the liganded-closed structure (2.9 and 2.0Å per residue for residues 121–127, respectively) (Fig. 4a, e). A single turn of 310-helix in this loop bearing the key MIDAS and ADMIDAS residue Ser 123 moves en bloc in the liganded-open structure, but the lesser movement in the liganded-closed structure disrupts this 310-helix.
Extensive movements occur in theb β6–aα7 loop and the α7-helix between the liganded-open and unliganded-closed structures. The β6–α7 loop moves downward, and the α7-helix moves downward and pivots laterally, resulting in an average displacement for residues 333–352 of 5.3Å (Fig. 4a, c, e). Between the unliganded-closed and liganded-closed structures there is a movement of lesser magnitude in the β6–α7 loop; however, the movements differ in direction (Fig. 4a, e). Movement in this region of the liganded-closed structure is therefore a consequence of strain rather than movement along the pathway towards the open conformation.
In the liganded-open compared with the unliganded-closed structure, the α1-helix moves32 upward to accommodate movements near its beginning at the MIDAS and ADMIDAS, and near its end, that allow hybrid domain swing-out (Fig. 4a). Furthermore, a bend between the 310-helix in the β1–α1 loop and the α1-helix is straightened, and the α1-helix is lengthened by five residues, as it pivots laterally to fill-in room vacated by the β6–α7 loop (Fig. 4a, c). The position of the α1-helix in the liganded-closed structure does not resemble that in the unliganded-closed or the liganded-open structures (Fig. 4a, e), suggesting that its position is off the pathway towards the open conformation, and results from strain imposed by binding to ligand when the interface with the hybrid domain remains in the closed conformation.
Changes in metal ion coordination are closely related to loop movements in the β I domain, and are key for stabilizing its alternative conformational states (Fig. 4d). Coordination of the Met 335 backbone carbonyl in the β6–α7 loop to the ADMIDAS Ca2+ ion in the unliganded-closed conformation (Fig. 4d)7 is broken in liganded-closed and Mn2+-bound-closed αVβ38, and in liganded-open αIIbβ3 (Fig. 4d). Mn2+ activates integrins by competing with Ca2+ at the ADMIDAS; the much lower propensity of Mn2+ than Ca2+ for carbonyl coordination enables downward displacement of the β6–α7 loop and activation in Mn2+ (ref. 33). Breakage of the Met 335 coordination and the movement of the β1–α1 loop with its coordinating residues enable the large movement in position of the ADMIDAS metal between the unliganded-closed and liganded-open conformations (Fig. 4d). Additionally, small shifts in the position of the MIDAS and LIMBS metals relate to marked movements and changes in metal ion coordination of residues Asp 251, Glu 220, Asn 215 and Asp 217 (Fig. 4d). The metal ions seem to occupy similar but less strained orientations in the liganded-open compared with the liganded-closed structures, with the caveat that the resolutions are 2.7 and 3.3Å, respectively. For example, the Asp 217 side chain coordinates with the LIMBS metal ion in the liganded-open structure, instead of orienting away from it in the liganded-closed structure8,33 (Fig. 4d). Its position in the liganded-open structure is more consistent with the function of Asp 217 in β7 as a LIMBS residue that stabilizes the high-affinity state33.
Rearrangements in the β I domain are clearly structurally homologous to those in α I domains (Fig. 4a, b). Movements of similar directionality occur in the MIDAS metal ion, β1–α1 loop, a 1-helix, β6–α7 loop anda α7-helix4. Hydrophobic ratchet residues that are located one turn of 310-helix apart, stabilize alternative β6–α7 loop positions in both α I and β I domains. In contrast to the one-turn displacement in the intermediate27 and two-turn displacement in the open α I domain conformations25,26 (Fig. 4b), a one-turn displacement occurs in the open β I domain conformation (Fig. 4a, c). Val 340, located in an upper hydrophobic pocket in the closed conformation, moves to a lower hydrophobic pocket in the open conformation, displacing Leu 343 (Fig. 4c). Movement of the a 1-helix plays a similar part in activation of α I and β I domains by accompanying the movement of metal-coordinating residues in the β1–α1 loop; however, the greater magnitude of α1-helix movement in the β I domain is accompanied by a unique ratchet-like movement: residue Leu 134 in the a 1-helix moves laterally to occupy the upper hydrophobic pocket vacated by Val 340 (Fig. 4b).
Hybrid domain swing-out
The piston-like displacement of the β I domain a α7-helix, which connects to the hybrid domain βC strand, results in complete remodelling of the interface between these domains (Figs 4a and 5a, b; Supplementary Movie 1). The interface in the closed conformation covers 1,350Å2 and includes at its centre hydrogen-bonding residues Tyr 110, Tyr 348 and Arg 3527. Upon opening not only does the α7-helix move downward, but the last two residues unwrap from the helix, including Arg 352, which reorients to the exterior of the interface. The more extended conformation at the junction betweena α7 and βC, and the straightening of the angle between α7 and βC, augment the effect of α7 displacement on hybrid domain swing-out. The more extended, end-to-end orientation between the βI and hybrid domains results in a smaller interface of about 800Å2 (Figs 4a and 5a, b). Near its centre the interface contains Tyr 110 and Tyr 348, which adopt new hydrogen-bonding partners (Fig. 5b). Reorganization of hydrogen-bonded interfaces is the general mechanism for allosteric transitions34. The smaller size of the open β I/hybrid interface allows some flexibility. Relative to the closed conformation, the hybrid domain swings out 698 in crystal form A, and 57°, 59° and 61° in the three molecules in crystal form B (Fig. 2b).
Structure of an integrin PSI domain
The structure of a PSI domain in an integrin (Fig. 2a and Supplementary Fig. 3b) and comparison to that in semaphorin 4D35 demonstrate the predicted homology of these domains in plexins, semaphorins and integrins36, and an unexpected insertion. The buried β1 strand bearing the invariant tryptophan, and the disulphide-bonded α1- and α2-helices are well conserved, but other regions differ significantly, including the longer α3-helix (Fig. 5c, d). All three shared disulphide bonds superimpose well, and a fourth shared with integrins, plexins and the growth factor receptor MET, but not semaphorins, is also revealed (Fig. 5c, d). Chemical assignment of disulphides in the integrin β3 PSI domain was difficult because cysteines are so closely spaced in sequence37; the structural data reassigns all of these disulphides, including the long-range disulphide, which was previously identified as Cys 5 to Cys 435, and is now shown to link Cys 13 to Cys 435 (Fig. 5d, e and Supplementary Fig. 3b). The long-range disulphide superimposes well with the highly conserved intradomain disulphide that links the second cysteine to the last cysteine in the PSI domain of plexins and semaphorins (Fig. 5c), and this second cysteine aligns perfectly in all PSI domains, maintaining its relationship to the third cysteine in the conservedα2-helix (Fig. 5d). These findings suggest that β3 Cys 435 is the eighth cysteine of the PSI domain, and an integral part of the PSI domain fold. Therefore, there seems to be a nested domain insertion in the β3 structure: the β I domain is inserted in the hybrid domain, which is in turn inserted in the PSI domain (Fig. 5e).
Superposition of four independent molecules shows that the 860Å2 interface between the hybrid and PSI domain is rigid (Fig. 2c). Arg 93 of the hybrid domain, which is invariant in vertebrate integrins, inserts its side chain into the centre of the interface, making hydrogen bonds to one hybrid domain residue and three different PSI domain residues (Fig. 5f). Rigidity of the interface is further supported by the nearby Cys 13-Cys 435, Cys 16-Cys 38 and Cys 26-Cys49 disulphides in the PSI domain, and the Cys 406-Cys 433 disulphide in the hybrid domain (Fig. 5f). The connection to integrin EGF-like (I-EGF) domain 1 may also be rigid, because a portion of it containing residues 437–440, including Cys 437 that is predicted to be disulphide-linked within I-EGF138, is present in the structure and stabilized by main-chain–side-chain and side-chain–side-chain hydrogen bonds with the PSI domain.
The human platelet alloantigen HPA-1 or PlA system, of great importance for neonatal alloimmune thrombocytopenia and post-transfusion purpura, corresponds to a leucine/proline polymorphism at PSI residue 33 (ref. 39). Our structure shows that the Leu 33 side chain is well exposed to solvent (Fig. 2a) on a loop of the PSI domain that is flexible and particularly long in integrins (Fig. 5c, d). Polymorphic substitution of the distally located residue Arg 93 at the hybrid/PSI interface (Fig. 5f) disrupts the HPA-1a epitope40, demonstrating the importance of the interface for structural integrity of the PSI domain. The I-EGF1 domain also participates in the HPA-1 epitope41, further emphasizing the tight linkage between the hybrid, PSI and I-EGF1 domains.
Allosteric mechanism for integrin activation
The structural rearrangements demonstrated here between the closed and open conformations seem to be general for all integrins. The effects of mutations designed to induce hybrid domain swing-out9,42 (Fig. 2d), allosteric activating or inhibitory mAb that bind to the hybrid domain10,13 (Supplementary Fig. 4), disulphide cross-links in the β6–α7 loop43 and shortening of the α7-helix in the βI domain44, all support the conclusion that the closed and open conformations of the integrin headpiece have low and high affinity for ligand, respectively. Furthermore, these experiments have been conducted on β1, β2, β3 and β7 integrins, demonstrating the generality of our findings. Moreover, the structural rearrangements shown here are consistent with exposure of LIBS and activation epitopes, including on the PSI domain in models of the complete integrin ectodomain (Supplementary Materials).
Our study reveals the βI/hybrid domain interface as the epicentre for quaternary structural rearrangements in integrins. A movement of about 10Å occurs at the junction between the βI domain α7-helix and the hybrid domainb C-strand that results in a 62° pivot at the βI/hybrid domain interface. The rigidly connected hybrid and PSI domains act as a mechanical lever in the upper β leg that amplifies and transmits β I domain allostery to the knee between the upper and lower β legs, resulting in a 70Å displacement at the PSI domain. Because the PSI domain is near the β knee between I-EGF1 and I-EGF2, and in the closed conformation of the headpiece the β knee is near the α-subunit knee or genu, the two legs must separate by about 70Å at their knees (Fig. 1b, c). Swing-out of the upperb leg could readily occur if it were preceded by extension at the αa and β knees (Fig. 1d to 1e to 1g). Electron microscopy studies show that below the PSI domain, the β leg is flexible in the extended conformation, whereas when the a leg extends, it adopts a single favoured orientation3. Interestingly, swing-out of the upper β leg might also occur in the bent conformation (Fig. 1d to 1f), because if the β subunit upper and lower legs moved as a rigid body, there would be no clash with the α subunit, facilitating conformational equilibration, and despite the 70Å separation at the knees, the C termini of the α and β subunit ectodomains would only move apart by 15Å. Thus, adjustments in the flexible β subunit lower leg domains could allow the α and β subunit transmembrane domains to remain associated during upper leg swing-out in the bent conformation (Fig. 1d to 1f to 1g). Transmembrane domain separation could thus occur as a later event in the process of integrin activation by ligand from outside the cell (Fig. 1g to 1h), whereas transmembrane domain separation is a key early step in activation by signals from within the cell3,16 (Fig. 1d to 1e to 1j to 1h, or Fig. 1d to 1i to 1j to 1h). In the bent αVβ3 integrin conformation, there are large, hydrophilic interfaces of 2,000Å2 each between the headpiece and the legs, and between the α and β subunit legs3. The latter interface would be disrupted by upper β leg swing-out, thereby weakening that between the headpiece and the legs, and facilitating adoption of the extended integrin conformation with the open headpiece observed for liganded integrins by electron microscopy3,6 (Fig. 1c and 1h).
Our crystal structures, together with previous structural studies on integrins3,6–8,12,15,38, now provide a clear picture of the confor mational rearrangements in the integrin head that regulate affinity for ligand, and how conformational signals are transmitted to the leg domains. Further structures are needed to define I-EGF domains 1 and 2 in both the bent and extended conformations, the apparently unique conformation of the α subunit genu in the extended conformation3, and how allostery is communicated between the β I and α I domains4.
Methods
Protein expression, purification and crystallization
For details and references, see Supplementary Materials. Briefly, the soluble αIIbβ3 headpiece encompassing residues 1–621 of αiib and residues 1–472 of β3 was expressed in CHO Lec 3.2.8.1 cells with an ACID-BASE coiled-coil clasp at the C termini, as described for soluble αIIbβ345, except that a hexahistidine tag was fused to the C terminus of β3. The expressed protein was purified by ammonium sulphate precipitation, Ni-NTA affinity chromatography and size exclusion chromatography (Superdex 200 HR), concentrated to 1 mg ml21, and treated with chymotrypsin at 25 °C for 16 h. The unclasped (coiled-coil and His6 tag removed)αIIbβ3 protein was collected in the flow-through of a second Ni-NTA chromatography step. The purified αIIbβ3 was mixed with the 10E5 Fab (1:1.1 molar ratio) and the complex was purified by Superdex 200 chromatography. The complex was subjected to digestion with carboxypeptidase A and B (Calbiochem) (1:100 weight ratio) in the presence of 1 mM ZnCl2 at 25 °C for 16 h. A stable protease resistant core of αIIbβ3 was obtained and further purified by a final Superdex 200 chromatography step and stored in TBS plus calcium and magnesium, and used to obtain crystal form A. To obtain crystal form B, αIIbβ3 fragment purified through the second Ni-NTA chromatography step was mixed with an excess of the purified fibrinogeng γ chain C-terminal domain fragment (see Supplementary Information) in the presence of 1 mM MnCl2 and subjected to carboxypeptidase A and B treatment. This resulted in the same pattern ofαIIbβ3 digestion as for the 10E5 Fab complex sample; however, little of the fibrinogen domain co-purified with the αIIbβ3 headpiece upon Superdex 200 chromatography, probably owing to hydrolysis of theαIIbβ3-binding C-terminal residues of the fibrinogeng γ chain by carboxypeptidase. This material was used to obtain crystal form B, which contains no fibrinogen fragment.
The Topaz crystallizer (Fluidigm) was used to identify initial crystallization conditions by free interfacial diffusion and the lead conditions were optimized with hanging-drop vapour diffusion. The final optimized well solution for form A crystals of the 10E5 Fab: αIIbβ3 complex is 11% PEG 3350, 0.7 M magnesium acetate and 0.1 M sodium cacodylate, pH 6.5, and for crystal form B is 10% PEG 8000, 0.4 M magnesium acetate and 0.1 M sodium cacodylate, pH 7.0. Acetate and 4 °C temperature were absolutely required for crystallization. To obtain co-crystals with the drugs, protein sample was mixed with each drug at 1:3 to 1:5 molar ratios before setting up the hanging drops. The optimized crystallization conditions were 10–12% PEG 3350, 0.7 M magnesium acetate and 0.1 M imidazole (pH 6.5) in place of cacodylate.
Structure determination
Diffraction data were collected at the 19-ID station of the Advanced Photon Source (APS) at the Argonne National Laboratory and the A-1 station of the Cornell High Energy Synchrotron Source (CHESS). The structure of crystal form A was determined by molecular replacement using search models of theb I domain and theb I domain plus the β-propeller from αVβ3 (PDB ID 1L5G), and a murine Fab 36–71 (PDB ID 6FAB). Electron density maps calculated using phases from the search models clearly showed the presence of the hybrid domain, plus difference densities in the CDR loops of the Fab. The hybrid domain was placed in density and rebuilt. Excellent densities for landmark residues Phe 56, Pro 57, Pro 68 and Leu 69 in the first β-strand of the hybrid domain and multiple nearby disulphide bonds in the hybrid and PSI domains (Fig. 5f and Supplementary Fig. 3a) necessitated a change in the sequence-to-structure register of thisb -strand. The structure of the PSI domain was built on the basis of the electron density maps computed with refined models and guided by the secondary structure arrangements in the sema4D crystal structure35. Strong electron density for the conserved disulphides, the single tryptophan and the secondary structures allowed unambiguous tracing of the whole domain. Continuous electron density extends beyond residue Cys 435 and allowed the building of residues Ala 436 to Gln 440 of I-EGF1, although alternative conformations of these residues cannot be ruled out. The structure of crystal form B was solved by molecular replacement using the αIIbβ3 structure in crystal form A as a search model. The structures of the drug bound αIIbβ3 were solved by molecular replacement using the native structure as a search model. Electron density for the bound drug molecules was readily discernible in the maps calculated with the molecular replacement solution.
Supplementary Material
Acknowledgements
We thank colleagues in the Springer laboratory for supporting data and stimulating discussions, B. Kessler for tandem mass spectrometry, E. Yvonne Jones at Oxford for sema4D coordinates, members of the J.H.W. and M. Eck laboratories and the staff at APS and CHESS for assistance with crystallography, M. Gerstein and N. Echols (Yale University) for the morphing script used in producing movies, and Y. Cheng for help with comparing crystal structures and the electron microscopy map. Supported by NIH grants to T.A.S., J.H.W. and B.S.C.
Footnotes
Atomic coordinates and structural factors have been deposited with the Protein Data Bank with the accession codes 1TY3 (form A + cacodylate 1); 1TXV (form A + cacodylate 2); 1TY5 (form A + tirofiban); 1TY6 (form A + eptifibatide); 1TY7 (form A + L-739758); 1TYE (form B + cacodylate). Sequences of the with GenBank.
Supplementary Information accompanies the paper on www.nature.com/nature.
Competing interests statement The authors declare competing financial interests: details accompany the paper on www.nature.com/nature.
References
- 1.Hughes PE, Pfaff M. Integrin affinity modulation. Trends Cell Biol. 1998;8:359–364. doi: 10.1016/s0962-8924(98)01339-7. [DOI] [PubMed] [Google Scholar]
- 2.Takagi J, Springer TA. Integrin activation and structural rearrangement. Immunol. Rev. 2002;186:141–163. doi: 10.1034/j.1600-065x.2002.18613.x. [DOI] [PubMed] [Google Scholar]
- 3.Takagi J, Petre BM, Walz T, Springer TA. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell. 2002;110:599–611. doi: 10.1016/s0092-8674(02)00935-2. [DOI] [PubMed] [Google Scholar]
- 4.Springer TA, Wang J.-h. In: Cell Surface Receptors. Garcia KC), editor. Elsevier; San Diego: 2004. [Google Scholar]
- 5.Coller BS. Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J. Clin. Invest. 1997;99:1467–1471. doi: 10.1172/JCI119307. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Takagi J, Strokovich K, Springer TA, Walz T. Structure of integrina α5β1 in complex with fibronectin. EMBO J. 2003;22:4607–4615. doi: 10.1093/emboj/cdg445. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Xiong J-P, et al. Crystal structure of the extracellular segment of integrina αVβ3. Science. 2001;294:339–345. doi: 10.1126/science.1064535. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Xiong JP, et al. Crystal structure of the extracellular segment of integrina αVβ3 in complex with an Arg-Gly-Asp ligand. Science. 2002;296:151–155. doi: 10.1126/science.1069040. [DOI] [PubMed] [Google Scholar]
- 9.Luo B-H, Springer TA, Takagi J. Stabilizing the open conformation of the integrin headpiece with a glycan wedge increases affinity for ligand. Proc. Natl Acad. Sci. USA. 2003;100:2403–2408. doi: 10.1073/pnas.0438060100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Luo B-H, Strokovich K, Walz T, Springer TA, Takagi J. Allosteric β1 integrin antibodies that stabilize the low affinity state by preventing the swing-out of the hybrid domain. J. Biol. Chem. 2004;279:27466–27471. doi: 10.1074/jbc.M404354200. [DOI] [PubMed] [Google Scholar]
- 11.Luo B-H, Springer TA, Takagi J. High affinity ligand binding by integrins does not involve head separation. J. Biol. Chem. 2003;278:17185–17189. doi: 10.1074/jbc.M301516200. [DOI] [PubMed] [Google Scholar]
- 12.Mould AP, et al. Structure of an integrin-ligand complex deduced from solution X-ray scattering and site-directed mutagenesis. J. Biol. Chem. 2003;278:39993–39999. doi: 10.1074/jbc.M304627200. [DOI] [PubMed] [Google Scholar]
- 13.Mould AP, et al. Conformational changes in the integrin βA domain provide a mechanism for signal transduction via hybrid domain movement. J. Biol. Chem. 2003;278:17028–17035. [Google Scholar]
- 14.Du X, et al. Ligands “activate” integrina αIIbβ3 (platelet GPIIb-IIIa). Cell. 1991;65:409–416. doi: 10.1016/0092-8674(91)90458-b. [DOI] [PubMed] [Google Scholar]
- 15.Adair BD, Yeager M. Three-dimensional model of the human platelet integrina αIIbβ3 based on electron cryomicroscopy and X-ray crystallography. Proc. Natl Acad. Sci. USA. 2002;99:14059–14064. doi: 10.1073/pnas.212498199. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Luo B-H, Springer TA, Takagi J. A specific interface between integrin transmembrane helices and affinity for ligand. PLoS Biol. 2004;2:776–786. doi: 10.1371/journal.pbio.0020153. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Vinogradova O, et al. A structural mechanism of integrina αIIbβ3 “inside-out” activation as regulated by its cytoplasmic face. Cell. 2002;110:587–597. doi: 10.1016/s0092-8674(02)00906-6. [DOI] [PubMed] [Google Scholar]
- 18.Kim M, Carman CV, Springer TA. Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins. Science. 2003;301:1720–1725. doi: 10.1126/science.1084174. [DOI] [PubMed] [Google Scholar]
- 19.Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J. Clin. Invest. 1983;72:325–338. doi: 10.1172/JCI110973. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Kamata T, Tieu KK, Springer TA, Takada Y. Amino acid residues in the αIIb subunit that are critical for ligand binding to integrina αIIbβ3 are clustered in theβ-propeller model. J. Biol. Chem. 2001;276:44275–44283. doi: 10.1074/jbc.M107021200. [DOI] [PubMed] [Google Scholar]
- 21.Artoni A, et al. The specificity determining loop and α helix 1 on human integrin β3 determine the binding of murine monoclonal antigbody 7E3 toa αIIbβ3: implications for the mechanism of integrin activation. Proc. Natl Acad. Sci. USA. 2004 in the press. [Google Scholar]
- 22.Zavortink M, Bunch TA, Brower DL. Functional properties of alternatively spliced forms of the Drosphila PS2 integrina subunit. Cell Adhes. Commun. 1993;1:251–264. doi: 10.3109/15419069309097258. [DOI] [PubMed] [Google Scholar]
- 23.von der Mark H, et al. Alternative splice variants of α7β1 integrin selectivity recognize different laminin isoforms. J. Biol. Chem. 2002;277:6012–6016. doi: 10.1074/jbc.M102188200. [DOI] [PubMed] [Google Scholar]
- 24.Springer TA. Predicted and experimental structures of integrins and β-propellers. Curr. Opin. Struct. Biol. 2002;12:802–813. doi: 10.1016/s0959-440x(02)00384-6. [DOI] [PubMed] [Google Scholar]
- 25.Lee J-O, Rieu P, Arnaout MA, Liddington R. Crystal structure of the A domain from the α subunit of integrin CR3 (CD11b/CD18). Cell. 1995;80:631–638. doi: 10.1016/0092-8674(95)90517-0. [DOI] [PubMed] [Google Scholar]
- 26.Lee J-O, Bankston LA, Arnaout MA, Liddington RC. Two conformations of the integrin A-domain (I-domain): a pathway for activation? Structure. 1995;3:1333–1340. doi: 10.1016/s0969-2126(01)00271-4. [DOI] [PubMed] [Google Scholar]
- 27.Shimaoka M, et al. Structures of the α L I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation. Cell. 2003;112:99–111. doi: 10.1016/s0092-8674(02)01257-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Scarborough RM, Gretler DD. Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J. Med. Chem. 2000;43:3453–3473. doi: 10.1021/jm000022w. [DOI] [PubMed] [Google Scholar]
- 29.Gottschalk KE, Kessler H. The structures of integrins and integrin-ligand complexes: implications for drug design and signal transduction. Angew. Chem. Int. Edn Engl. 2002;41:3767–3774. doi: 10.1002/1521-3773(20021018)41:20<3767::AID-ANIE3767>3.0.CO;2-T. [DOI] [PubMed] [Google Scholar]
- 30.Egbertson MS, et al. Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation. J. Med. Chem. 1999;42:2409–2421. doi: 10.1021/jm980722p. [DOI] [PubMed] [Google Scholar]
- 31.Scarborough RM, et al. Design of potent and specific integrin antagonists. J. Biol. Chem. 1993;268:1066–1073. [PubMed] [Google Scholar]
- 32.Mould AP, et al. Integrin activation involves a conformational change in the α 1 helix of the β subunit A-domain. J. Biol. Chem. 2002;277:19800–19805. doi: 10.1074/jbc.M201571200. [DOI] [PubMed] [Google Scholar]
- 33.Chen JF, Salas A, Springer TA. Bistable regulation of integrin adhesiveness by a bipolar metal ion cluster. Nature Struct. Biol. 2003;10:995–1001. doi: 10.1038/nsb1011. [DOI] [PubMed] [Google Scholar]
- 34.Perutz MF. Mechanisms of cooperativity and allosteric regulation in proteins. Q. Rev. Biophys. 1989;22:139–237. doi: 10.1017/s0033583500003826. [DOI] [PubMed] [Google Scholar]
- 35.Love CA, et al. The ligand-binding face of the semaphorins revealed by the high-resolution crystal structure of SEMA4D. Nature Struct. Biol. 2003;10:843–848. doi: 10.1038/nsb977. [DOI] [PubMed] [Google Scholar]
- 36.Bork P, Doerks T, Springer TA, Snel B. Domains in plexins: Links to integrins and transcription factors. Trends Biochem. Sci. 1999;24:261–263. doi: 10.1016/s0968-0004(99)01416-4. [DOI] [PubMed] [Google Scholar]
- 37.Calvete JJ, Henschen A, González-Rodríguez J. Assignment of disulphide bonds in human platelet GPIIIa. A disulphide pattern for the β-subunits of the integrin family. Biochem. J. 1991;274:63–71. doi: 10.1042/bj2740063. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Beglova N, Blacklow SC, Takagi J, Springer TA. Cysteine-rich module structure reveals a fulcrum for integrin rearrangement upon activation. Nature Struct. Biol. 2002;9:282–287. doi: 10.1038/nsb779. [DOI] [PubMed] [Google Scholar]
- 39.Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J. Clin. Invest. 1989;83:1778–1781. doi: 10.1172/JCI114082. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Watkins NA, et al. HPA-1a phenotype-genotype discrepancy reveals a naturally occurring Arg93Gln substitution in the platelet β3 integrin that disrupts the HPA-1a epitope. Blood. 2002;99:1833–1839. doi: 10.1182/blood.v99.5.1833. [DOI] [PubMed] [Google Scholar]
- 41.Kunicki TJ, et al. The P1A alloantigen system is a sensitive indicator of the structural integrity of the amino-terminal domain of the human integrin β3 subunit. Blood Cells Mol. Dis. 1995;21:131–141. doi: 10.1006/bcmd.1995.0015. [DOI] [PubMed] [Google Scholar]
- 42.Chen JF, et al. The relative influence of metal ion binding sites in the I-like domain and the interface with the hybrid domain on rolling and firm adhesion by integrina α4β7. J. Biol. Chem. doi: 10.1074/jbc.M407773200. in the press. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Luo B-H, Takagi J, Springer TA. Locking the β3 integrin I-like domain into high and low affinity conformations with disulfides. J. Biol. Chem. 2004;279:10215–10221. doi: 10.1074/jbc.M312732200. [DOI] [PubMed] [Google Scholar]
- 44.Yang W, Shimaoka M, Chen JF, Springer TA. Activation of integrin β subunit I-like domains by one-turn C-terminala α-helix deletions. Proc. Natl Acad. Sci. USA. 2004;101:2333–2338. doi: 10.1073/pnas.0307291101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Takagi J, Erickson HP, Springer TA. C-terminal opening mimics “inside-out” activation of integrina α5β1. Nature Struct. Biol. 2001;8:412–416. doi: 10.1038/87569. [DOI] [PubMed] [Google Scholar]
- 46.Esnouf RM. An extensively modified version of MolScript that includes greatly enhanced coloring capabilities. J. Mol. Graph. Model. 1997;15:132–138. doi: 10.1016/S1093-3263(97)00021-1. [DOI] [PubMed] [Google Scholar]
- 47.Merritt EA, Murphy MEP. Raster 3D version 2.0: a program for photorealistic graphics. Acta Crystallogr. D. 1994;50:869–873. doi: 10.1107/S0907444994006396. [DOI] [PubMed] [Google Scholar]
- 48.Carson M. Ribbons. Methods Enzymol. 1997;277:493–505. [PubMed] [Google Scholar]
- 49.Puzon-McLaughlin W, Kamata T, Takada Y. Multiple discontinuous ligand-mimetic antibody binding sites define a ligand binding pocket in integrina αIIbβ3. J. Biol. Chem. 2000;275:7795–7802. doi: 10.1074/jbc.275.11.7795. [DOI] [PubMed] [Google Scholar]
- 50.Tozer EC, Liddington RC, Sutcliffe MJ, Smeeton AH, Loftus JC. Ligand binding to integrinαIIbβ3 is dependent on a MIDAS-like domain in the β3 subunit. J. Biol. Chem. 1996;271:21978–21984. doi: 10.1074/jbc.271.36.21978. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.